



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 April 2021
EMA/COMP/173664/2021
Human Medicines Division

Committee for Orphan Medicinal Products (COMP)

Draft agenda for the meeting on 13-15 April 2021

Chair: Violeta Stoyanova-Beninska

13 April 2021, 08:30-19:30, remote virtual meeting

14 April 2021, 08:30-19:30, remote virtual meeting

15 April 2021, 08:30-17:00, remote virtual meeting

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members and experts.....	5
1.2.	Adoption of agenda.....	5
1.3.	Adoption of the minutes	5
2.	Applications for orphan medicinal product designation	5
2.1.	For opinion	5
2.1.1.	- EMA/OD/0000049059	5
2.1.2.	- EMA/OD/0000049823	5
2.1.3.	- EMA/OD/0000050198	5
2.1.4.	- EMA/OD/0000047784	5
2.1.5.	- EMA/OD/0000047579	5
2.1.6.	- EMA/OD/0000037733	6
2.2.	For discussion / preparation for an opinion.....	6
2.2.1.	- EMA/OD/0000037664	6
2.2.2.	- EMA/OD/0000037706	6
2.2.3.	- EMA/OD/0000042650	6
2.2.4.	- EMA/OD/0000044418	6
2.2.5.	- EMA/OD/0000046486	6
2.2.6.	- EMA/OD/0000048861	6
2.2.7.	- EMA/OD/0000049844	6
2.2.8.	- EMA/OD/0000051199	6
2.2.9.	- EMA/OD/0000051718	7
2.2.10.	- EMA/OD/0000051869	7
2.2.11.	- EMA/OD/0000052176	7
2.2.12.	- EMA/OD/0000052224	7
2.2.13.	- EMA/OD/0000052449	7
2.2.14.	- EMA/OD/0000052825	7
2.2.15.	- EMA/OD/0000052862	7
2.2.16.	- EMA/OD/0000052866	7
2.2.17.	- EMA/OD/0000052925	7
2.2.18.	- EMA/OD/0000053087	8
2.2.19.	- EMA/OD/0000056143	8
2.2.20.	- EMA/OD/0000045928	8
2.3.	Revision of the COMP opinions	8
2.4.	Amendment of existing orphan designations.....	8
2.5.	Appeal	8
2.6.	Nominations	8

2.6.1.	New applications for orphan medicinal product designation - Appointment of COMP rapporteurs.....	8
2.7.	Evaluation on-going.....	8
3.	Requests for protocol assistance with significant benefit question	9
3.1.	Ongoing procedures	9
3.1.1.	-.....	9
3.1.2.	-.....	9
3.1.3.	-.....	9
3.1.4.	-.....	9
3.2.	Finalised letters.....	9
3.2.1.	-.....	9
3.2.2.	-.....	9
3.3.	New requests.....	9
3.3.1.	-.....	9
4.	Review of orphan designation for orphan medicinal products at time of initial marketing authorisation	10
4.1.	Orphan designated products for which CHMP opinions have been adopted	10
4.1.1.	Efmody - hydrocortisone - EMEA/H/C/005105/0000, EU/3/05/296, EMA/OD/0000032128	10
4.2.	Orphan designated products for discussion prior to adoption of CHMP opinion	10
4.2.1.	- satralizumab - EMEA/H/C/004788, EMA/OD/014/16, EU/3/16/1680, EMA/OD/0000016001	10
4.2.2.	- selumetinib - EMEA/H/C/005244/0000, EMA/OD/045/18, EU/3/18/2050, EMA/OD/0000033877	10
4.2.3.	- elivaldogene autotemcel - EMEA/H/C/003690/0000, EMA/OD/009/12, EU/3/12/1003, EMA/OD/0000044429	10
4.2.4.	- odevixibat - EMEA/H/C/004691/0000, EMA/OD/022/12, EU/3/12/1028, EMA/OD/0000048989	10
4.3.	Appeal	10
4.4.	On-going procedures	11
4.5.	Orphan Maintenance Reports.....	11
5.	Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension	11
5.1.	After adoption of CHMP opinion.....	11
5.2.	Prior to adoption of CHMP opinion.....	11
5.3.	Appeal	11
5.4.	On-going procedures	11
6.	Application of Article 8(2) of the Orphan Regulation	11
7.	Organisational, regulatory and methodological matters	11
7.1.	Mandate and organisation of the COMP	11
7.1.1.	Strategic Review & Learning meetings.....	11

7.1.2.	Protocol Assistance Working Group (PAWG)	11
7.1.3.	Election of COMP Vice-Chairperson.....	12
7.2.	Coordination with EMA Scientific Committees or CMDh-v	12
7.2.1.	Recommendation on eligibility to PRIME – report	12
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	12
7.3.1.	Working Party with Patients’ and Consumers’ Organisations (PCWP)	12
7.3.2.	Working Party with Healthcare Professionals’ Organisations (HCPWP).....	12
7.4.	Cooperation within the EU regulatory network	12
7.4.1.	European Commission	12
7.5.	Cooperation with International Regulators.....	12
7.5.1.	Food and Drug Administration (FDA)	12
7.5.2.	Japanese Pharmaceuticals and Medical Devices Agency (PMDA).....	12
7.5.3.	Therapeutic Goods Administration (TGA), Australia	12
7.5.4.	Health Canada.....	13
7.6.	Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee	13
7.7.	COMP work plan	13
7.8.	Planning and reporting	13
7.8.1.	List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2021	13
7.8.2.	Overview of orphan marketing authorisations/applications.....	13
8.	Any other business	13
8.1.	Inter-Committee SAG Oncology	13
8.2.	Data Standards Strategy survey and workshop	13
8.3.		13
9.	Explanatory notes	14

1. Introduction

1.1. Welcome and declarations of interest of members and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 13-15 April 2021. See April 2021 COMP minutes (to be published post May 2021 COMP meeting).

1.2. Adoption of agenda

COMP agenda for 13-15 April 2021.

1.3. Adoption of the minutes

COMP minutes for 16-18 March 2021.

2. Applications for orphan medicinal product designation

2.1. For opinion

2.1.1. - [EMA/OD/0000049059](#)

Treatment of generalised pustular psoriasis (GPP)

Action: For adoption, Oral explanation to be held on 13 April 2021 at 13:30

2.1.2. - [EMA/OD/0000049823](#)

Treatment of cystic fibrosis

Action: For adoption, Oral explanation to be held on 14 April 2021 at 15:30

2.1.3. - [EMA/OD/0000050198](#)

Treatment of glioma

Action: For adoption, Oral explanation to be held on 13 April 2021 at 17:00

2.1.4. - [EMA/OD/0000047784](#)

Treatment of multiple system atrophy

Action: For adoption, Oral explanation to be held on 14 April 2021 at 09:00

2.1.5. - [EMA/OD/0000047579](#)

Treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma

Action: For adoption, Oral explanation to be held on 13 April 2021 at 16:00

2.1.6. - [EMA/OD/0000037733](#)

Treatment of systemic sclerosis

Action: For information

Notes: Withdrawal request received on 29 March 2021.

2.2. For discussion / preparation for an opinion

2.2.1. - [EMA/OD/0000037664](#)

Treatment of cystinuria

Action: For discussion/adoption

2.2.2. - [EMA/OD/0000037706](#)

Treatment of dermatomyositis

Action: For discussion/adoption

2.2.3. - [EMA/OD/0000042650](#)

Treatment of functional single ventricle heart disease

Action: For discussion/adoption

2.2.4. - [EMA/OD/0000044418](#)

Treatment of neuroblastoma

Action: For discussion/adoption

2.2.5. - [EMA/OD/0000046486](#)

Treatment of Barth syndrome

Action: For discussion/adoption

2.2.6. - [EMA/OD/0000048861](#)

Treatment of fragile X syndrome

Action: For discussion/adoption

2.2.7. - [EMA/OD/0000049844](#)

Treatment of solid organ transplantation

Action: For discussion/adoption

2.2.8. - [EMA/OD/0000051199](#)

Treatment of Huntington's disease

Action: For discussion/adoption

2.2.9. - EMA/OD/0000051718

Treatment of hyperphenylalaninemia

Action: For discussion/adoption

2.2.10. - EMA/OD/0000051869

Treatment of pulmonary arterial hypertension

Action: For discussion/adoption

2.2.11. - EMA/OD/0000052176

Treatment of amyotrophic lateral sclerosis (ALS)

Action: For discussion/adoption

2.2.12. - EMA/OD/0000052224

Treatment of beta thalassemia intermedia and major

Action: For discussion/adoption

2.2.13. - EMA/OD/0000052449

Treatment of marginal zone lymphoma

Action: For discussion/adoption

2.2.14. - EMA/OD/0000052825

Treatment of retinitis pigmentosa

Action: For discussion/adoption

2.2.15. - EMA/OD/0000052862

Treatment of X-linked severe combined immunodeficiency (X-SCID)

Action: For discussion/adoption

2.2.16. - EMA/OD/0000052866

Treatment of essential thrombocythaemia

Action: For discussion/adoption

2.2.17. - EMA/OD/0000052925

Treatment of Leber's congenital amaurosis

Action: For discussion/adoption

2.2.18. - EMA/OD/0000053087

Treatment of Rett syndrome

Action: For discussion/adoption

2.2.19. - EMA/OD/0000056143

Treatment of malignant hyperthermia

Action: For discussion/adoption

2.2.20. - EMA/OD/0000045928

Treatment of nasopharyngeal cancer

Action: For discussion/adoption

2.3. Revision of the COMP opinions

None

2.4. Amendment of existing orphan designations

None

2.5. Appeal

None

2.6. Nominations

2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs

Action: For adoption

Document(s) tabled:

OMPD applications - appointment of coordinators at the 13-15 April 2021 COMP meeting

2.7. Evaluation on-going

21 applications for orphan designation will not be discussed as evaluation is ongoing.

Action: For information

3. Requests for protocol assistance with significant benefit question

3.1. Ongoing procedures

3.1.1. -

Treatment of mucopolysaccharidosis type I

Action: For adoption

3.1.2. -

Treatment of glioma

Action: For adoption

3.1.3. -

Diagnosis of AL amyloidosis

Action: For adoption

3.1.4. -

Treatment of Gaucher disease

Action: For adoption

3.2. Finalised letters

3.2.1. -

Treatment of pancreatic cancer

Action: For information

3.2.2. -

Treatment of growth hormone deficiency

Action: For information

3.3. New requests

3.3.1. -

Treatment of transthyretin-mediated amyloidosis in patients with cardiomyopathy

Action: For information

4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation

4.1. Orphan designated products for which CHMP opinions have been adopted

- 4.1.1. Efmody - hydrocortisone - EMEA/H/C/005105/0000, EU/3/05/296, EMA/OD/0000032128

Diurnal Europe B.V.; Treatment of congenital adrenal hyperplasia

Action: For adoption, Oral explanation to be held on 14 April 2021 at 13:30

4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

- 4.2.1. – satralizumab - EMEA/H/C/004788, EMA/OD/014/16, EU/3/16/1680, EMA/OD/0000016001

Roche Registration GmbH; Treatment of neuromyelitis optica spectrum disorders

Action: For adoption

- 4.2.2. – selumetinib - EMEA/H/C/005244/0000, EMA/OD/045/18, EU/3/18/2050, EMA/OD/0000033877

AstraZeneca AB; Treatment of neurofibromatosis type 1

Action: For discussion/adoption

- 4.2.3. – elivaldogene autotemcel - EMEA/H/C/003690/0000, EMA/OD/009/12, EU/3/12/1003, EMA/OD/0000044429

Accelerated Assessment bluebird bio (Netherlands) B.V; Treatment of adrenoleukodystrophy

Action: For adoption

- 4.2.4. – odeixibat - EMEA/H/C/004691/0000, EMA/OD/022/12, EU/3/12/1028, EMA/OD/0000048989

Accelerated Assessment Albireo; Treatment of progressive familial intrahepatic cholestasis

Action: For discussion/adoption

4.3. Appeal

None

4.4. On-going procedures

Action: For information

Document(s) tabled:

Review of orphan designation for OMP for MA - On-going procedures

4.5. Orphan Maintenance Reports

Action: For information

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

5.1. After adoption of CHMP opinion

None

5.2. Prior to adoption of CHMP opinion

None

5.3. Appeal

None

5.4. On-going procedures

Action: For information

Document(s) tabled:

Review of orphan designation for OMP for MA extension - On-going procedures

6. Application of Article 8(2) of the Orphan Regulation

None

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the COMP

7.1.1. Strategic Review & Learning meetings

None

7.1.2. Protocol Assistance Working Group (PAWG)

Proposed meeting time on 9 April 2021 at 13:30

Document tabled:

7.1.3. Election of COMP Vice-Chairperson

Action: For adoption

7.2. Coordination with EMA Scientific Committees or CMDh-v

7.2.1. Recommendation on eligibility to PRIME – report

None

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP)

None

7.3.2. Working Party with Healthcare Professionals' Organisations (HCPWP)

None

7.4. Cooperation within the EU regulatory network

7.4.1. European Commission

None

7.5. Cooperation with International Regulators

7.5.1. Food and Drug Administration (FDA)

Action: For information

Notes:

Monthly teleconference

7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

Action: For information

Notes:

Ad hoc basis meeting

7.5.3. Therapeutic Goods Administration (TGA), Australia

Action: For information

Notes:

Ad hoc basis meeting

7.5.4. Health Canada

Action: For information

Notes:

Ad hoc basis meeting

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

None

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2021

Action: For information

7.8.2. Overview of orphan marketing authorisations/applications

Action: For information

8. Any other business

8.1. Inter-Committee SAG Oncology

Action: For discussion

8.2. Data Standards Strategy survey and workshop

Action: For discussion

8.3.

Action: For discussion

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

Abbreviations / Acronyms

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

EC: European Commission

OD: Orphan Designation

PA: Protocol Assistance

PDCO: Paediatric Committee

PRAC: Pharmacovigilance and Risk Assessment Committee

SA: Scientific Advice

SAWP: Scientific Advice Working Party

Orphan Designation (*section 2 Applications for orphan medicinal product designation*)

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures (including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

Protocol Assistance (*section 3 Requests for protocol assistance with significant benefit question*)

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

Sponsor

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

Maintenance of Orphan Designation (*section 4 Review of orphan designation for orphan medicinal products for marketing authorisation*).

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from

the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

More detailed information on the above terms can be found on the EMA website:

www.ema.europa.eu/